ClinicalTrials.gg
CompletedNCT06672718Updated Aug 25, 2026

A Study of SPY002-091 in Healthy Volunteers

A Phase 1 interventional study of SPY002-091 and Placebo in Healthy, sponsored by Spyre Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Spyre Therapeutics, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Spyre Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women
  • Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits

Exclusion criteria

Exclusion Criteria:

  • Participation in more than one cohort
  • Evidence of abnormality or disease
  • Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
  • History of severe allergic reactions or
  • Donation or loss of >1 unit of whole blood within 1 month prior to dosing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    SAD Cohorts 1-5, Experimental Arm

    Participants will receive a single dose of SPY002-091 in a dose escalation format

    Drug: SPY002-091

  • Placebo comparator
    SAD Cohorts 1-5, Placebo Arm

    Participants will receive a single dose of placebo

    Other: Placebo

  • Experimental
    SAD Cohort 6 Experimental Arm

    Participants of Chinese descent will receive a single dose of SPY002-091

    Drug: SPY002-091

  • Placebo comparator
    SAD Cohorts 6 Placebo Arm

    Participants of Chinese descent will receive a single dose of placebo

    Other: Placebo

Interventions

  • DrugSPY002-091

    Experimental

    Also known as: SPY002

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events

    Incidence, severity, and causal relationship of TEAEs

    Time frame: Up to 40 weeks

Secondary outcomes

  1. Cmax

    Maximum concentration after single ascending doses

    Time frame: Up to 40 weeks

  2. Tmax

    Time to reach maximum concentration after single ascending doses

    Time frame: Up to 40 weeks

  3. AUC

    Area under the curve after single ascending doses

    Time frame: Up to 40 weeks

  4. t1/2

    Half life after single ascending doses

    Time frame: Up to 40 weeks

  5. ADA

    Incidence of anti-drug antibody after single ascending doses

    Time frame: Up to 40 weeks

07

Study locations

1 site
  • Spyre Site 1
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Aug 2026, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Nov 26, 2024
Primary completionActual
Aug 19, 2026
CompletionActual
Aug 19, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672718
Lead sponsor
Spyre Therapeutics, Inc.
Collaborators
Altasciences Company Inc.
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Nov 26, 2024
Primary completion
Aug 19, 2026
Completion
Aug 19, 2026
Last update
Aug 25, 2026

Study contacts

Joshua Friedman, MD
study chair · Spyre Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion